An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL
Cancer Discov. 2017 7 (6): 575-585

PMID: 28274957 · PMCID: PMC5457707 · DOI:10.1158/2159-8290.CD-16-1431

MeSH Terms (14)

Afatinib Antineoplastic Agents Breast Neoplasms Cell Line, Tumor Drug Resistance, Neoplasm Female Humans Middle Aged Mutation Phenotype Protein Kinase Inhibitors Quinazolines Quinolines Receptor, ErbB-2

Connections (4)

This publication is referenced by other Labnodes entities: